Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE vs CALCITRIOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.
Calcitriol, the active form of vitamin D, binds to vitamin D receptors (VDR) in target tissues, modulating gene transcription. It increases intestinal calcium and phosphate absorption, enhances renal tubular reabsorption of calcium, and promotes bone mineralization by stimulating osteoblast activity.
Moderate to severe pain relief; combinations are used to reduce abuse potential.
Management of hypocalcemia in patients undergoing chronic renal dialysis,Secondary hyperparathyroidism in patients with chronic kidney disease not yet on dialysis,Hypoparathyroidism (post-surgical, idiopathic, or pseudohypoparathyroidism),Off-label: Vitamin D-dependent rickets type I and II, osteoporosis (as an adjunct)
Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.
0.25-0.5 mcg orally once daily, may increase by 0.25 mcg/day at 4-8 week intervals; maximum 2 mcg/day.
Pentazocine has an elimination half-life of 2-3 hours in healthy adults, which may be prolonged in patients with hepatic impairment. Naloxone has a terminal half-life of 0.5-1.5 hours in adults, with a rapid decline in plasma levels; the short half-life limits its duration of opioid antagonism.
5–8 hours (terminal) in normal renal function; prolonged up to 18–24 hours in chronic kidney disease (CKD) due to reduced clearance.
Pentazocine is metabolized primarily by hepatic conjugation (glucuronidation) and oxidation via CYP2C19 and CYP2D6; naloxone is extensively metabolized by the liver, primarily via glucuronidation (UGT2B7).
Primarily metabolized in the kidney and intestine via 24-hydroxylase (CYP24A1) to inactive metabolites (e.g., calcitroic acid). No major hepatic cytochrome P450 involvement.
Pentazocine is primarily metabolized in the liver and excreted in urine as conjugates of glucuronide and sulfate, with about 60% of a dose excreted renally within 24 hours as metabolites and unchanged drug (less than 5% unchanged). Naloxone undergoes extensive hepatic metabolism to naloxone-3-glucuronide, which is excreted renally; approximately 50% of a dose is excreted as conjugates in urine within 6 hours.
Renal (fecal after biliary excretion of metabolites): ~10% unchanged in urine; ~70% as metabolites in feces via bile.
Pentazocine: Approximately 35-65% bound to plasma proteins (mainly albumin). Naloxone: Approximately 32-45% bound to plasma proteins (mainly albumin).
~99% bound to vitamin D-binding protein (DBP) and albumin.
Pentazocine: Vd ~2-3 L/kg, indicating extensive tissue distribution. Naloxone: Vd ~2-3 L/kg, also indicating wide distribution.
0.5–1.0 L/kg (indicates extensive tissue distribution, primarily to kidney, intestine, bone).
Oral pentazocine: 20-30% due to first-pass metabolism. Intramuscular pentazocine: 100%. Subcutaneous pentazocine: 100%. Oral naloxone: <2% due to extensive first-pass metabolism. Intramuscular and subcutaneous naloxone: 100%. Intravenous: 100% for both.
Oral: ~70% (rapidly absorbed from small intestine). Intravenous: 100%.
GFR 30-50 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8-12 hours; GFR <10 m L/min: Administer every 12 hours or consider alternative.
GFR 15-59 m L/min: initial dose 0.25 mcg orally once daily; GFR <15 m L/min: avoid use or use with caution, dose adjustment not established.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% or extend interval; Child-Pugh Class C: Avoid use.
No specific guidelines for Child-Pugh; use with caution in severe hepatic impairment as calcitriol metabolism may be altered.
Not recommended for children under 12 years. For older children (≥12 years): Pentazocine 50 mg (with naloxone 0.5 mg) orally every 3-4 hours as needed; maximum 6 tablets daily.
Neonates and children: initial 0.25 mcg orally once daily; may increase by 0.25 mcg at 2-4 week intervals as needed; maximum 2 mcg/day.
Initiate with half the usual adult dose (one-half tablet) and titrate carefully due to increased sensitivity and risk of respiratory depression.
Start at low end of dosing range (0.25 mcg once daily) due to possible decreased renal function; monitor serum calcium and phosphorus closely.
Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of life-threatening respiratory depression when used with benzodiazepines or other CNS depressants.
None officially designated by FDA. However, excessive administration may lead to hypercalcemia, hypercalciuria, and hyperphosphatemia, with risk of soft tissue calcification and renal toxicity.
Respiratory depression; hypotension; increased intracranial pressure; seizure risk (pentazocine); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; interaction with MAOIs; risk of dependence and withdrawal; gastrointestinal obstruction; impaired renal or hepatic function; head injury.
Hypercalcemia risk: avoid excessive dosing; monitor serum calcium, phosphate, and alkaline phosphatase regularly,Hypercalciuria: may cause nephrolithiasis; maintain adequate hydration,Digitalis toxicity: hypercalcemia increases risk; monitor cardiac status,Adynamic bone disease: excessive suppression of PTH in dialysis patients may lead to low bone turnover,Aluminum intoxication: concurrent use of aluminum-containing phosphate binders may increase toxicity
Hypersensitivity to pentazocine or naloxone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; patients receiving MAOIs or within 14 days.
Hypercalcemia or evidence of vitamin D toxicity,Hypersensitivity to calcitriol or any component of the formulation,Hyperphosphatemia (unless adequately managed)
No specific food interactions are reported for this combination. However, grapefruit juice may theoretically affect metabolism via CYP3A4 (pentazocine is metabolized by CYP3A4), but clinical significance is unknown. Advise patients to maintain a consistent diet.
High dietary calcium intake may increase risk of hypercalcemia; advise consistent calcium intake per healthcare provider. No specific restrictions with other foods.
Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Third trimester: Chronic use may cause fetal dependence; neonatal withdrawal syndrome reported. High doses near term may cause neonatal respiratory depression.
Calcitriol is the active form of vitamin D. At therapeutic doses, no increased risk of major malformations has been consistently demonstrated. However, excessive doses (hypercalcemia) during pregnancy can lead to fetal hypercalcemia, aortic stenosis, retinopathy, and intellectual disability. First trimester: No clear teratogenicity at normal doses. Second and third trimesters: Maternal hypercalcemia from overdosage may cause fetal hypercalcemia and adverse effects. Avoid doses causing maternal serum calcium >11 mg/d L.
Pentazocine is excreted in breast milk in small amounts (estimated relative infant dose <3%). Naloxone is poorly bioavailable orally. Generally considered compatible with breastfeeding; monitor infant for sedation or poor feeding. M/P ratio for pentazocine is approximately 1.0.
Calcitriol is present in breast milk in low concentrations. The M/P ratio is approximately 0.3–0.4. At maternal therapeutic doses, risk to the infant is minimal. Monitor infant serum calcium if maternal high doses are used.
No established dose adjustments for pregnancy; however, pharmacokinetic changes (increased volume of distribution, enhanced clearance) may require higher or more frequent doses of pentazocine for adequate analgesia. Use lowest effective dose and shortest duration.
Pregnancy may increase vitamin D metabolism; however, calcitriol dose adjustments are generally not required for normal pregnancies. In cases of maternal hypoparathyroidism or renal disease, dosing may need adjustment based on serum calcium levels, as increased maternal blood volume and renal clearance may decrease calcitriol levels. Titrate to maintain normocalcemia.
Naloxone in this fixed-dose combination is included to deter opioid abuse by reversing euphoria. The pentazocine component is a mixed agonist-antagonist opioid; naloxone has poor oral bioavailability but becomes active parenterally, precipitating withdrawal in opioid-dependent individuals. Use with caution in patients with impaired renal or hepatic function. Monitor for respiratory depression, especially in opioid-naive patients, as pentazocine alone can cause respiratory depression.
Monitor serum calcium and phosphate levels regularly; hypercalcemia risk especially with thiazide diuretics or high calcium intake. Calcitriol has a rapid onset (hours) and short half-life, making it ideal for acute management of hypocalcemia. Avoid concurrent use of magnesium-containing antacids due to risk of hypermagnesemia.
Take exactly as prescribed; do not crush or inject tablets, as injected naloxone can cause severe withdrawal in opioid-dependent individuals.,This medication contains naloxone to discourage misuse; injection will cause withdrawal symptoms.,Report any signs of withdrawal (e.g., nausea, vomiting, sweating, agitation) or breathing difficulty.,Avoid alcohol and other central nervous system depressants as they increase risk of respiratory depression.,Do not use with other opioids unless directed, as effects are unpredictable.,Keep out of reach of children; accidental ingestion may cause severe respiratory depression.
Take exactly as prescribed, usually once daily with or without food.,Do not take additional calcium or vitamin D supplements without consulting your doctor.,Report symptoms of hypercalcemia: nausea, vomiting, constipation, muscle weakness, confusion, or irregular heartbeat.,Avoid excessive intake of calcium-rich foods (e.g., dairy products) unless advised.,Store at room temperature away from light and moisture.
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
"Dexamethasone, a potent glucocorticoid, induces the expression of the enzyme 24-hydroxylase (CYP24A1), which accelerates the catabolism of calcitriol (1,25-dihydroxyvitamin D3) into inactive metabolites. This reduces the bioavailability and therapeutic efficacy of calcitriol, potentially leading to inadequate control of hypocalcemia in patients with chronic kidney disease or hypoparathyroidism. Clinically, this interaction may manifest as declining serum calcium levels or worsening bone mineral density despite calcitriol therapy."
"Calcitriol, the active form of vitamin D, may reduce the serum concentration of aripiprazole through a proposed mechanism involving induction of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein (P-gp) efflux transporter. This interaction could lead to decreased systemic exposure of aripiprazole, potentially compromising its antipsychotic efficacy. Clinically, patients may experience worsening of psychotic symptoms or require dose adjustments of aripiprazole when coadministered with calcitriol."
"Calcitriol, the active form of vitamin D, may inhibit the metabolism of delavirdine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), by competing for or downregulating cytochrome P450 (CYP) enzymes, particularly CYP3A4. This can lead to elevated delavirdine plasma concentrations, increasing the risk of dose-related adverse effects such as hepatotoxicity, rash, and central nervous system toxicity. Clinically, patients may experience enhanced delavirdine toxicity without a corresponding increase in antiretroviral efficacy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE vs CALCITRIOL, answered by our medical review team.
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.. CALCITRIOL is a Vitamin D Analog that works by Calcitriol, the active form of vitamin D, binds to vitamin D receptors (VDR) in target tissues, modulating gene transcription. It increases intestinal calcium and phosphate absorption, enhances renal tubular reabsorption of calcium, and promotes bone mineralization by stimulating osteoblast activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE and CALCITRIOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is: Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.. The standard adult dose of CALCITRIOL is: 0.25-0.5 mcg orally once daily, may increase by 0.25 mcg/day at 4-8 week intervals; maximum 2 mcg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE and CALCITRIOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Thi. CALCITRIOL is classified as Category A/B. Calcitriol is the active form of vitamin D. At therapeutic doses, no increased risk of major malformations has been consistently demonstrated. However, excessive doses (hypercalcem. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.